Tempus AI, Inc. (NASDAQ:TEM) Given Consensus Rating of "Hold" by Analysts

Key Points

• Analysts have a consensus “Hold” rating on Tempus AI, with 11 buys, eight holds and two sells among 21 firms. The average 12-month price target is $69.33.
• Tempus AI reported quarterly revenue of $382.49 million, up 21.6% year over year, and an adjusted EPS loss of $0.04 that beat estimates; analysts expect a full-year loss of $1.38 per share.
• The stock opened at $69.97, while insider selling totaled 1.04 million shares worth approximately $57 million over the past 90 days. Insiders own 24.26% of the company, and institutional investors own 24.22%.

Tempus AI, Inc. (NASDAQ:TEM - Get Free Report) has earned an average rating of "Hold" from the twenty-one ratings firms that are presently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have given a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $69.3333.

Several analysts recently commented on the stock. Stifel Nicolaus reduced their target price on shares of Tempus AI from $60.00 to $50.00 and set a "hold" rating for the company in a report on Monday, August 3rd. Rothschild & Co Redburn began coverage on shares of Tempus AI in a report on Tuesday, September 8th. They issued a "neutral" rating and a $67.00 price target on the stock. Roth Capital began coverage on shares of Tempus AI in a research report on Tuesday, September 8th. They set a "neutral" rating and a $67.00 price objective for the company. BTIG Research raised their price objective on shares of Tempus AI from $70.00 to $80.00 and gave the stock a "buy" rating in a research report on Thursday, August 20th. Finally, Guggenheim boosted their price objective on Tempus AI from $60.00 to $65.00 and gave the stock a "buy" rating in a report on Thursday, July 16th.

Tempus AI Stock Up 1.6%

TEM stock opened at $69.97 on Thursday. The company has a current ratio of 3.30, a quick ratio of 3.16 and a debt-to-equity ratio of 3.06. The firm has a market capitalization of $12.62 billion, a PE ratio of -48.59 and a beta of 3.72. Tempus AI has a 1-year low of $40.77 and a 1-year high of $104.32. The business's 50 day simple moving average is $56.42 and its 200 day simple moving average is $52.53.

Tempus AI (NASDAQ:TEM - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The business had revenue of $382.49 million during the quarter, compared to the consensus estimate of $379.69 million. During the same quarter last year, the firm posted ($0.22) EPS. The company's quarterly revenue was up 21.6% on a year-over-year basis. As a group, research analysts anticipate that Tempus AI will post -1.38 EPS for the current year.

Insider Transactions at Tempus AI

In other Tempus AI news, CEO Eric P. Lefkofsky sold 250,000 shares of the company's stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $42.06, for a total value of $10,515,000.00. Following the transaction, the chief executive officer directly owned 200,000 shares of the company's stock, valued at $8,412,000. This represents a 55.56% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Ryan Fukushima sold 41,095 shares of the stock in a transaction on Tuesday, August 18th. The stock was sold at an average price of $49.61, for a total value of $2,038,722.95. Following the transaction, the chief executive officer owned 562,463 shares in the company, valued at $27,903,789.43. The trade was a 6.81% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 1,043,988 shares of company stock worth $56,963,417 in the last ninety days. 24.26% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Tempus AI

Several institutional investors and hedge funds have recently modified their holdings of the business. EMC Capital Management acquired a new stake in Tempus AI in the 2nd quarter worth about $29,000. Whittier Trust Co. grew its position in shares of Tempus AI by 190.0% during the 1st quarter. Whittier Trust Co. now owns 870 shares of the company's stock worth $41,000 after purchasing an additional 570 shares in the last quarter. CoreCap Advisors LLC grew its position in shares of Tempus AI by 293.4% during the 2nd quarter. CoreCap Advisors LLC now owns 1,019 shares of the company's stock worth $59,000 after purchasing an additional 760 shares in the last quarter. Global Assets Advisory LLC bought a new position in shares of Tempus AI during the first quarter worth approximately $46,000. Finally, Eurizon Capital SGR S.p.A. bought a new position in shares of Tempus AI in the fourth quarter worth $70,000. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI, Inc is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.